Icotrokinra Sustains Psoriasis Skin Clearance Through 2 Years
Two-year ICONIC-LEAD data show oral IL-23 receptor antagonist icotrokinra sustained skin clearance in plaque psoriasis, strengthening its case against injectable biologics.
Topic
Dermatology
Topic
Dermatology
Early Psoriatic Arthritis Screening Can Prevent Irreversible Damage
Dermatologists see psoriasis patients years before rheumatology does. Friedman argues that window is the chance to catch psoriati…
Sun Pharma commits $2.5M to dermatology professorship
Sun Pharmaceutical Industries will fund a $2.5 million dermatology professorship, NJBIZ reported, in one of the larger recent ind…
Tulisokibart posts first positive Phase II anti-TL1A read-out
Merck's tulisokibart produced the first positive Phase II efficacy data for an anti-TL1A antibody in a dermatologic indication, o…
AI Cuts Skin Cancer Waiting Times in Bradford
Bradford has cut skin cancer waiting times using new AI technology, the BBC reports, as NHS dermatology services face rising urge…
Foundation Models Usher In a New AI Era for Dermatology
Medscape charts dermatology AI's shift from task-specific CNNs to foundation models — adaptable, multimodal systems that could mo…
Major Review Maps Persistent Care Gap for Melanoma Survivors
A major review reported by Bioengineer.org maps effective post-treatment interventions for melanoma survivors and identifies an u…
Tempo Therapeutics Wins $2.25M NIH Grant for MAP Wound Healing
Tempo Therapeutics has received a $2.25 million NIH grant to advance its MAP wound healing technology, a step toward new options…
Dermatologist Elected Chair of House Health Panel
The House of Representatives has elected a dermatologist to chair its health panel, Inquirer.net reports, giving a skin physician…